Therapy  	Therapy  	 JJ	O
refractory  	refractory  	 JJ	B-NP
menorrhagia  	menorrhagia  	 NN	I-NP
as  	as  	 IN	O
first  	first  	 JJ	O
manifestation  	manifestation  	 NN	B-NP
of  	of  	 IN	I-NP
Hermansky-Pudlak  	Hermansky-Pudlak  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
Oculocutaneous  	Oculocutaneous  	 FW	I-NP
albinism  	albinism  	 FW	I-NP
( 	( 	 -LRB-	O
OCA 	OCA 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
a  	a  	 DT	O
platelet  	platelet  	 JJ	B-NP
function  	function  	 NN	I-NP
defect  	defect  	 VBZ	O
caused  	caused  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
disturbed  	disturbed  	 JJ	O
release  	release  	 NN	B-NP
reaction  	reaction  	 NN	I-NP
from  	from  	 IN	O
platelet  	platelet  	 JJ	B-NP
δ-granules  	δ-granules  	 NN	I-NP
( 	( 	 -LRB-	O
storage  	storage  	 NN	B-NP
pool  	pool  	 NN	I-NP
defect  	defect  	 NN	I-NP
-  	-  	 :	O
SPD 	SPD 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
typical  	typical  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
autosomal  	autosomal  	 JJ	B-NP
recessive  	recessive  	 NN	I-NP
inherited  	inherited  	 VBD	I-NP
Hermansky-Pudlak  	Hermansky-Pudlak  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
( 	( 	 -LRB-	O
HPS 	HPS 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
girl  	girl  	 NN	O
( 	( 	 -LRB-	O
age 	age 	 NN	O
:  	:  	 :	O
13  	13  	 CD	O
years 	years 	 NNS	O
)  	)  	 -RRB-	O
with  	with  	 IN	O
OCA  	OCA  	 NNP	B-NP
was  	was  	 VBD	O
hospitalized  	hospitalized  	 VBN	O
with  	with  	 IN	O
transfusion-requiring  	transfusion-requiring  	 JJ	B-NP
menorrhagia 	menorrhagia 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
suspicion  	suspicion  	 NN	O
of  	of  	 IN	O
HPS  	HPS  	 NNP	B-NP
was  	was  	 VBD	O
confirmed  	confirmed  	 VBN	O
by  	by  	 IN	O
results  	results  	 NNS	O
of  	of  	 IN	O
lumi-aggregometry 	lumi-aggregometry 	 JJ	B-NP
.  	.  	 .	O
Suspecting  	Suspecting  	 VBG	O
a  	a  	 DT	O
disorder  	disorder  	 NN	O
in  	in  	 IN	O
primary  	primary  	 JJ	B-NP
haemostasis  	haemostasis  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
with  	with  	 IN	O
tranexamic  	tranexamic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
( 	( 	 -LRB-	O
10  	10  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 JJ	I-NP
body  	body  	 NN	I-NP
weight  	weight  	 NN	I-NP
every  	every  	 DT	O
8  	8  	 CD	O
h  	h  	 CD	B-NP
i.  	i.  	 CD	I-NP
v. 	v. 	 CD	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
desmopressin  	desmopressin  	 NNS	B-NP
( 	( 	 -LRB-	O
0.3  	0.3  	 CD	O
µg 	µg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 JJ	I-NP
body  	body  	 NN	I-NP
weight  	weight  	 NN	I-NP
every  	every  	 DT	O
8  	8  	 CD	O
to  	to  	 TO	O
12  	12  	 CD	O
h 	h 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
hormonal  	hormonal  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
( 	( 	 -LRB-	O
norethisterone 	norethisterone 	 LS	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
started  	started  	 VBN	O
but  	but  	 CC	O
the  	the  	 DT	O
menorrhagia  	menorrhagia  	 JJ	B-NP
persisted 	persisted 	 NN	I-NP
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
response  	response  	 NN	I-NP
was  	was  	 VBD	O
finally  	finally  	 RB	O
achieved  	achieved  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
injection  	injection  	 NN	B-NP
of  	of  	 IN	O
100  	100  	 CD	O
µg 	µg 	 FW	B-NP
/ 	/ 	 FW	I-NP
kg  	kg  	 FW	I-NP
body  	body  	 FW	I-NP
weight  	weight  	 FW	I-NP
recombinant  	recombinant  	 FW	O
factor  	factor  	 FW	B-NP
VIIa  	VIIa  	 FW	I-NP
( 	( 	 -LRB-	O
rFVIIa 	rFVIIa 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
diagnosis  	diagnosis  	 NN	O
of  	of  	 IN	O
HPS  	HPS  	 NNP	B-NP
should  	should  	 MD	O
be  	be  	 VB	O
suspected  	suspected  	 VBN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
OCA  	OCA  	 NNP	B-NP
and  	and  	 CC	O
bleeding  	bleeding  	 VBG	B-NP
symptoms  	symptoms  	 NNS	I-NP
and  	and  	 CC	O
is  	is  	 VBZ	O
confirmed  	confirmed  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
proof  	proof  	 NN	O
of  	of  	 IN	O
SPD 	SPD 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
case  	case  	 NN	O
of  	of  	 IN	O
absent  	absent  	 JJ	O
clinical  	clinical  	 JJ	B-NP
response  	response  	 NN	I-NP
to  	to  	 TO	O
desmopressin  	desmopressin  	 VB	O
the  	the  	 DT	O
application  	application  	 NN	O
of  	of  	 IN	O
rFVIIa  	rFVIIa  	 NNP	B-NP
should  	should  	 MD	O
be  	be  	 VB	O
considered 	considered 	 VBN	O
.  	.  	 .	O
Hormones  	Hormones  	 NNP	O
and  	and  	 CC	O
antifibrinolytics  	antifibrinolytics  	 NNS	B-NP
are  	are  	 VBP	O
useful  	useful  	 JJ	O
options  	options  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
extensive  	extensive  	 JJ	B-NP
menorrhagia 	menorrhagia 	 NN	I-NP
.  	.  	 .	O
